Trends and Strategies to Combat Viral Infections: A Review on FDA Approved Antiviral Drugs

Overview

Journal Int J Biol Macromol

Publisher Elsevier

Date 2021 Jan 17

PMID 33454328

Citations 85

Authors

Dharma Rao Tompa

Aruldoss Immanuel

Srimari Srikanth

Saraboji Kadhirvel

Affiliations

Soon will be listed here.

Abstract

The infectious microscopic viruses invade living cells to reproduce themselves, and causes chronic infections such as HIV/AIDS, hepatitis B and C, flu, etc. in humans which may lead to death if not treated. Different strategies have been utilized to develop new and superior antiviral drugs to counter the viral infections. The FDA approval of HIV nucleoside reverse transcriptase inhibitor, zidovudine in 1987 boosted the development of antiviral agents against different viruses. Currently, there are a number of combination drugs developed against various viral infections to arrest the activity of same or different viral macromolecules at multiple stages of its life cycle; among which majority are targeted to interfere with the replication of viral genome. Besides these, other type of antiviral molecules includes entry inhibitors, integrase inhibitors, protease inhibitors, interferons, immunomodulators, etc. The antiviral drugs can be toxic to human cells, particularly in case of administration of combination drugs, and on the other hand viruses can grow resistant to the antiviral drugs. Furthermore, emergence of new viruses like Ebola, coronaviruses (SARS-CoV, SARS-CoV-2) emphasizes the need for more innovative strategies to develop better antiviral drugs to fight the existing and the emerging viral infections. Hence, we reviewed the strategic enhancements in developing antiviral drugs for the treatment of different viral infections over the years.

Citing Articles

Global burden of viral skin diseases from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.

Li D, Chen M, Li W, Xu X, Li Q Front Public Health. 2025; 13:1464372.

PMID: 40046109 PMC: 11879981. DOI: 10.3389/fpubh.2025.1464372.

Synthetic heparan sulfate mimics based on chitosan derivatives show broad-spectrum antiviral activity.

Revuelta J, Rusu L, Frances-Gomez C, Trapero E, Iglesias S, Pinilla E Commun Biol. 2025; 8(1):360.

PMID: 40038521 PMC: 11880534. DOI: 10.1038/s42003-025-07763-z.

Antiviral Agents: Structural Basis of Action and Rational Design.

Menendez-Arias L, Gago F Subcell Biochem. 2024; 105:745-784.

PMID: 39738962 DOI: 10.1007/978-3-031-65187-8_20.

The Bacteriocins Produced by Lactic Acid Bacteria and the Promising Applications in Promoting Gastrointestinal Health.

Ismael M, Huang M, Zhong Q Foods. 2024; 13(23).

PMID: 39682959 PMC: 11640443. DOI: 10.3390/foods13233887.

Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses.

Ridgway H, Apostolopoulos V, Moore G, Kate Gadanec L, Zulli A, Swiderski J Viruses. 2024; 16(11).

PMID: 39599890 PMC: 11599072. DOI: 10.3390/v16111776.

References

Zheng M, Song L . Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell Mol Immunol. 2020; 17(5):536-538. PMC: 7091851. DOI: 10.1038/s41423-020-0385-z. View

Cady S, Luo W, Hu F, Hong M . Structure and function of the influenza A M2 proton channel. Biochemistry. 2009; 48(31):7356-64. PMC: 2879269. DOI: 10.1021/bi9008837. View

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

Asselah T, Kowdley K, Zadeikis N, Wang S, Hassanein T, Horsmans Y . Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2017; 16(3):417-426. DOI: 10.1016/j.cgh.2017.09.027. View

Strauss E, Strauss J . Replication strategies of the single stranded RNA viruses of eukaryotes. Curr Top Microbiol Immunol. 1983; 105:1-98. DOI: 10.1007/978-3-642-69159-1_1. View

Gomez Ayerbe C, Santos Gonzalez J, Munoz R . Symtuza (DRV/c/FTC/TAF) in the management of treatment-naive HIV-patients. Enferm Infecc Microbiol Clin (Engl Ed). 2018; 36 Suppl 2:17-21. DOI: 10.1016/S0213-005X(18)30393-8. View

Reusken C, Haagmans B, Muller M, Gutierrez C, Godeke G, Meyer B . Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 2013; 13(10):859-66. PMC: 7106530. DOI: 10.1016/S1473-3099(13)70164-6. View

Kuiken T, Fouchier R, Schutten M, Rimmelzwaan G, van Amerongen G, van Riel D . Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003; 362(9380):263-70. PMC: 7112434. DOI: 10.1016/S0140-6736(03)13967-0. View

Andersen P, Ianevski A, Lysvand H, Vitkauskiene A, Oksenych V, Bjoras M . Discovery and development of safe-in-man broad-spectrum antiviral agents. Int J Infect Dis. 2020; 93:268-276. PMC: 7128205. DOI: 10.1016/j.ijid.2020.02.018. View

10.

Padhi A, Shukla R, Saudagar P, Tripathi T . High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance. iScience. 2021; 24(1):101992. PMC: 7807151. DOI: 10.1016/j.isci.2020.101992. View

11.

Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

12.

Reitano M, Tyring S, Lang W, Thoming C, Worm A, Borelli S . Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis. 1998; 178(3):603-10. DOI: 10.1086/515385. View

13.

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

14.

. Update: Outbreak of severe acute respiratory syndrome--worldwide, 2003. MMWR Morb Mortal Wkly Rep. 2003; 52(12):241-6, 248. View

15.

Chan J, Lau S, To K, Cheng V, Woo P, Yuen K . Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. 2015; 28(2):465-522. PMC: 4402954. DOI: 10.1128/CMR.00102-14. View

16.

de Groot R, Baker S, Baric R, Brown C, Drosten C, Enjuanes L . Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013; 87(14):7790-2. PMC: 3700179. DOI: 10.1128/JVI.01244-13. View

17.

Arvin A . Varicella-zoster virus. Clin Microbiol Rev. 1996; 9(3):361-81. PMC: 172899. DOI: 10.1128/CMR.9.3.361. View

18.

Chen S, Dou J, Temple R, Agarwal R, Wu K, Walker S . New therapies from old medicines. Nat Biotechnol. 2008; 26(10):1077-83. DOI: 10.1038/nbt1008-1077. View

19.

Kilbourne E . Influenza pandemics of the 20th century. Emerg Infect Dis. 2006; 12(1):9-14. PMC: 3291411. DOI: 10.3201/eid1201.051254. View

20.

Baba M, Pauwels R, Herdewijn P, De Clercq E, Desmyter J, Vandeputte M . Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun. 1987; 142(1):128-34. DOI: 10.1016/0006-291x(87)90460-8. View